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Abstract
Background: The first generation antihistamines, such as diphenhydramine, are fairly potent
muscarinic antagonists in addition to being H1 selective antihistamines. The antimuscarinic action
is often not desirable since it is in part responsible for the drying of secretions in the airways and
the sedative effect. We therefore examined a number of antihistamines for antimuscarinic effects
on ion transport by mucus gland cells isolated from the airways of swine. Enzymatically isolated
airway mucus gland cells were purified utilizing density gradients and grown in culture on porous
inserts (Millicell HA™) at an air interface. Cells grown in this manner maintain phenotype and
polarity. Transport of ions, as short-circuit current measured under voltage-clamp, was measured
in response to acetylcholine (ACh) or histamine applied to the serosal side of the gland cell layers.
Concentration-response relationships for ACh or histamine were generated in the presence and
absence of various drugs. The potencies against muscarinic receptor activation were estimated
using the dose-ratio method of Schild.
Results: Three known muscarinic antagonists were used to validate the system. Atropine had a
pA2 of 9.4 ± 0.1 (n = 9). 4-DAMP and methoctramine had pA2 values of 8.6 ± 0.1 and 5.6 ± 0.1,
respectively (n = 12, 11) all consistent with inhibition of an M3 subtype muscarinic receptor. The
rank order of potency of the antihistamines against the inhibition of M3 receptors was
desloratadine = diphenhydramine > hydroxyzine (pA2; 6.4, 6.2, 4.8, respectively). pA2 values for
fexofenadine, loratadine and cetirizine were not determined since they had no effect on the
cholinergic response at the highest drug concentrations tested (10, 10 and 100 µM, respectively).
The pA2 values for the antihistamines against the histamine response could not be calculated, but
the estimates of the rank order of potency were estimated to be desloratadine> cetirizine ≈
hydroxyzine > fexofenadine > loratadine > diphenhydramine.
Conclusion: The rank order of selectivity for histamine receptors over muscarinic receptors was
estimated to be cetirizine ≈  fexofenadine > loratadine > desloratadine ≥  hydroxyzine ≥
diphenhydramine.
Background
The airways are lined by epithelium and the upper airways
have mucus gland acini, all of which contribute to secre-
tion of both water and mucus coating the surface. The epi-
thelium forms a physical barrier to inhaled substances
and, actively secretes and absorbs fluid to provide an
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appropriate thickness hydrated layer on the surface of the
airways. The epithelium clears particulates from the air-
ways by ciliary action and ingestion by macrophages.
There is a local immune response to inhaled antigens in
part through resident macrophages and dendritic cells.
Epithelial function is controlled by neurotransmitters
(ACh for example) and blood born substances (epine-
phrine, norepinephrine, hormones) and substances
released from inflammatory cells (histamine and other
substances from mast cells). Several serious diseases are
linked to disfunction of the epithelium such as cystic
fibrosis and asthma. Therefore proper functioning of the
epithelium is critical for normal lung function.
Cholinergic stimulation of muscarinic receptors is known
to increase mucus secretion from submucosal gland cells
[1,2], fluid transport by submucosal gland cells [3], and
ciliary beat frequency of ciliated epithelium [4-6]. The
secretory functions are transient (ion, water and mucus),
occurring for several minutes during continuous stimula-
tion of the cells by ACh [1,7]. This synchrony makes sense
from a functional standpoint since mucus that is secreted
must be hydrated by secretion of fluid. The increase in
cilia beat frequency caused by muscarinic receptor activa-
tion can then clear the ejected and secreted mucus.
Histamine can also stimulate the release of mucus and
fluid by submucosal gland cells. The effects of ACh and
histamine on short circuit current (a measurement of ion
transport and therefore fluid movement) are transient,
reflecting the transient nature of the increase in secretion
of fluid. Stimulation of these cells by histamine probably
does not support normal secretions, but represents mast
cell degranulation, typically associated with the symp-
tomatology of a pathological state such as asthma or aller-
gies. The symptoms of airway irritation and
hypersecretion are commonly treated with antihistamines
except for the case of asthma, where excessive drying of
the mucus membranes by first-generation antihistamines
is considered a contraindication.
The antimuscarinic actions of first generation H1 selective
antihistamines are well known [8]. In fact, some of the
therapeutic efficacy of these drugs (e.g., drying of mucus
membranes) and side effects (e.g., drowsiness, thickening
of mucus, accelerated heart rate) may also be attributable
to these actions. Generally, the antimuscarinic actions of
the H1 selective antihistamines are undesirable, in partic-
ular in people with high blood pressure, arrhythmias or
asthma. H1 selective antihistamines devoid of antimus-
carinic properties should be useful in the treatment of
asthma since mast cell degranulation occurs during the
early phase of an asthma attack releasing histamine caus-
ing mucus secretion, inflammatory reactions in the airway
epithelium, vasodilation in the mucosa and contraction
of airway smooth muscle [9]. Each of these events leads to
a narrowing or stiffening of the airways and increased
resistance to air flow. Theoretically, H1 selective antihista-
mines devoid of antimuscarinic properties would
decrease the pathological effects of histamine without
altering the normal control of the cells in the airway by
ACh at muscarinic, M3, receptors. Yanni et al. [10] sug-
gested that an antihistamine, effective at both H1 and H2
receptors, lacking antimuscarinic actions, would be useful
in the treatment of asthma. Lee et al. [11] proposed that
selective H1 antihistamines could be useful in the treat-
ment of mild to moderate asthma and have additive
effects with leukotriene antagonists. Therefore, the follow-
ing experiments were performed to determine the
antimuscarinic actions of several antihistamines on mus-
carinic receptor induced increases in ion transport by
mucus gland cell epithelium grown in culture or porous
bottom inserts as measured using Ussing chamber
methodology.
Results
Antimuscarinic effects
After two days in culture the mucus gland cells have
formed confluent cell layers on the Millicell inserts and
current flow can be measured across the inserts. In Figure
1A the short circuit currents (∆ Isc) evoked by cumulative
addition of ACh are shown. The currents were used to gen-
erate concentration-response relationships for agonists on
changes in ∆ Isc(Fig 1B). The responses to both ACh and
histamine are phasic, particularly obvious at higher con-
centrations of agonist (>10-5 M). The maximum increase
in current was 19 ± 1 µA/cm2 (n = 21) for histamine and
15.5 ± 1 µA/cm2 (n = 32) for ACh. Also, illustrated in this
figure is the basic protocol used for all experiments. 10 µM
amiloride is added to the mucosal side of the mucus gland
cells to block fluid reabsorption. A small decrease in basal
current occurs indicative of the reabsorption of sodium
and fluid by the monolayer. The addition of the test drug
to the serosal chamber, in this case the prototypical mus-
carinic antagonist atropine, causes little change in base-
line current. After five minutes ACh is added cumulatively
to the serosal side of the cells. The concentrations are indi-
cated at the arrows. ACh was added at 5 to 6 second inter-
vals into each of the 4–6 Ussing chambers being used
during an experiment. Thus, the apparent "shift to the
right" that occurs in the response in the presence of atro-
pine in this figure is indicative of inhibition of the mus-
carinic receptors. The parallel shifts in the concentration-
response relationships to the right for ACh caused by atro-
pine are illustrated in Fig 1B for averaged peak data at each
agonist concentration normalized to the maximal
response for each insert. The method of Schild was used
to determine the apparent Ki for atropine as shown in Fig
2. The slope of the line through the data points is set to 1
(and not significantly different from 1) with the XBMC Pharmacology 2005, 5:8 http://www.biomedcentral.com/1471-2210/5/8
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A. This is a recording from a typical experiment to measure short-circuit current (∆ Isc) across the confluent epithelial monol- ayers grown in Millicell inserts Figure 1
A. This is a recording from a typical experiment to measure short-circuit current (∆ Isc) across the confluent epithelial monol-
ayers grown in Millicell inserts. Short circuit current (∆ Isc) is measured under voltage-clamp that maintains the potential differ-
ence across the epithelium at 0 mV. 10 µM amiloride was added in all experiments to the lumen side of the inserts to block 
absorption, which caused a decrease in the basal current as shown in Fig. 1A. In this recording, five minutes prior to cumulative 
addition of ACh, 3 inserts were exposed serosally to 10-9, 3 × 10-9, or 10-8 M atropine (red, green, and blue traces respec-
tively). The response to ACh reaches a peak and then declines. The difference of peak response to baseline line at each con-
centration of agonist was measured as the response to each concentration of ACh (n = 9) B. Concentration-response 
relationships were generated as the peak response to each concentration of ACh (normalized to the maximal response of the 
epithelium to ACh) plotted versus the ACh concentration. Atropine causes parallel shifts to the right in the concentration-
response relationships with increases in atropine concentration. Average data from 9 experiments. Data were then used to 
generate Schild plots shown in the next figure.
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intercept giving an estimate of the pA2 (-log Ki). The pA2
for atropine (determined by this method) was 9.4 ± 0.1(n
= 9). Subtype selective inhibitors of muscarinic receptors
were used to suggest which subtype of muscarinic receptor
was being activated by ACh to induce the increases in ∆ Isc.
4-Diphenylacetoxy-N-methylpiperidine (4-DAMP) is a
relatively selective antagonist for M3 muscarinic receptors
and methoctramine is a relatively selective antagonist for
m2 muscarinic receptors. The pA2 for these drugs was: 4-
DAMP 8.6 ± 0.1(n = 12); Methoctramine 5.6 ± 0.1(n =
11). These values are consistent with M3 receptor inhibi-
tion [12]. Therefore, the inhibitory constants given for
antihistamine block of muscarinic receptors are consid-
ered to be against the M3 subtype in the following
experiments.
Six antihistamines were tested for inhibition of the mus-
carinic receptor response in gland cells. The antihista-
Schild analysis of the concentration response data for the  muscarinic antagonists atropine, 4-DAMP, and  methoctramine Figure 2
Schild analysis of the concentration response data for the 
muscarinic antagonists atropine, 4-DAMP, and methoc-
tramine. The Log (DR-1) versus log inhibitor concentration is 
plotted in this figure. DR is the dose ratio, the ratio of con-
centrations of ACh giving equal responses (EC50 for this 
plot) in the absence and presence of test compound. The 
slope of the lines drawn through the data shown is 1. The X-
intercepts of the lines equal pA2values, which are equal to 
the -log Ki values, where Ki is the affinity of the antagonist. 
Schild plots are shown for atropine (red) a nonselective mus-
carinic antagonist (n = 9), 4-DAMP (green, n = 12), M3 selec-
tive, and methoctramine (black), m2 selective (n = 11).
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A. The effects of desloratadine on gland cell responses to  ACh are shown here Figure 3
A. The effects of desloratadine on gland cell responses to 
ACh are shown here. ∆ Isc in response to ACh are inhibited 
by desloratadine as shown by a shift to higher concentrations 
of ACh in the presence of increasing concentrations of 
desloratadine. B. The concentration response relationships 
derived from data in A. desloratadine causes a parallel shift to 
the right in the concentration response relationships for 
ACh. C. Schild analysis of these data and those for diphenhy-
dramine and hydroxyzine are presented.
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mines are: desloratadine, diphenhydramine, hydroxyzine,
loratadine, cetirizine, and fexofenadine. Each was exam-
ined using the protocol described for atropine. In addi-
tion, the antihistaminic activity of each compound was
confirmed by the ability of these drugs to block hista-
mine-induced increases in ∆ Isc. In figure 3A the effects of
desloratadine on the ∆ Isc induced by ACh are shown. As
with atropine there is a shift to the right in the concentra-
tion-response relationships (Fig 3B) that, when plotted
using the dose-ratio method of Schild, yields a linear plot
with slope of one (Fig 3C) and an estimated pA2 of 6.4 ±
0.1(n = 13).
The Schild plot for diphenhydramine and hydroxyzine is
also shown in Fig 3C. Their pA2 values are 6.2 ± 0.1(15)
and 4.8 ± 0.1(11), respectively. Hydroxyzine is much less
potent antagonist at muscarinic receptors than deslorata-
dine and diphenhydramine (p < 0.01). The active
A and C show that both cetirizine and fexofenadine had no effect on the response of gland cells to ACh Figure 4
A and C show that both cetirizine and fexofenadine had no effect on the response of gland cells to ACh. B and D: Concentra-
tion-response data generated from the peak increase in ∆ Isc induced by ACh. Note the lack of effect of cetirizine and 
fexofenadine.
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metabolite of hydroxyzine, cetirizine, has no effects on
muscarinic receptor activation (Fig 4A, 4B) even at very
high concentrations (10-4M). The precursor of deslorata-
dine, loratadine, had no antimuscarinic action (data not
shown). Fexofenadine had no antimuscarinic action at
concentrations up to 10 µM (Fig 4C, 4D). A compilation
of the pA2 values is presented in Table 1.
Antihistaminic effects
We did not perform Schild analysis on the antihistaminic
effects of the antihistamines because the underlying
assumptions were not met. The basic underlying assump-
tions of Schild analysis are: 1) the inhibition of a response
by the antagonist is competitive and 2) that during the
response, equilibrium of the antagonist and agonist for
the receptor is reached. While these requirements seem to
be met at least tacitly for muscarinic receptors, they do not
appear to be met for antagonism of the effects of hista-
mine. Fig 5A shows the ∆ Isc response to histamine. The
∆ Isc response declines rapidly after reaching a peak, even at
low concentrations of histamine. This provides little time
for equilibrium conditions to be met during the response.
In the case of diphenhydramine there is a shift to the right
in the concentration-response relationships for histamine
with little decrease in maximum response, as shown in Fig
5A and inset. The inset shows the resulting Schild plot
with an estimated pA2 of 6.5 ± 0.2 (n = 12) when the slope
the line shown in the inset was set to1. However, the least
squares fit to these data had a slope of 1.6 (statistically dif-
ferent from 1 (p < 0.05) and was curvilinear with esti-
mated pA2 of 10.8 ± 2.4. This finding suggested that the
underlying assumptions of the Schild analysis were not
met. This is more clearly illustrated for the case of fex-
ofenadine as shown in Fig 5B. Fexofenadine causes a
decrease in the maximum response to histamine and a
shift to the right in the concentration response relation-
ship. Using data such as shown in Fig 5B inset for
inhibition of peak response, we computed the "% of max-
imal control ∆ Isc" response (control inserts were run
simultaneously with each drug treated insert) for each of
the antihistamines; hydroxyzine, cetirizine, fexofenadine,
loratadine and desloratadine. A graph of these data is
shown in Fig 6. Desloratadine is the most potent antihis-
tamine in this group (50% reduction in peak ∆ Isc  at
approximately 2 × 10-8 M) and loratadine the least potent
(50% reduction in peak ∆ Isc at 10-5M). Table 1 gives a
compilation of the estimates of potency for all com-
pounds tested.
Discussion
In order to test the validity of using short-circuit current
responses for the measurement of pA2 values for inhibi-
tion of muscarinic receptors, we first examined the effect
of classical muscarinic receptor inhibitors on the ACh-
induced currents. As shown in Table 1 the pA2 estimated
for atropine was 9.4. This value is in good agreement with
estimates from many other tissues (range 8.9–9.8, [12].
The pA2 values suggest that the muscarinic receptor prima-
rily responsible for the increase in short-circuit current is
the M3 subtype since the values estimated for methoc-
tramine and 4-DAMP were 5.6 and 8.6, respectively. The
rank order of these values is similar to those given by Cau-
field and Birdsall [12] for inhibition of M1 and M3 recep-
tors, although closer to the ranges given for M3 than M1.
We have previously demonstrated two receptor subtypes
in submucosal gland cells, which at the time were desig-
nated M1 and M2G [13], corresponding to the current
designations of M1 and M3. Culp et al. [14] concluded
that both M1 and M3 receptors were capable of inducing
secretory responses in mucus glands cells from sublingual
glands and that M3 receptors were sufficient to give a max-
imal response. We suggest that the increase in short-circuit
Table 1: 
Drug aMuscarinic inhibition (pA2) N H1 receptor inhibition (~1/2 max-µM) N
Atropine 9.4 ± 0.1 9 ND
Methoctramine 5.6 ± 0.1 11 ND
4-DAMP 8.6 ± 0.1 12 ND
Diphenhydramine 6.2 ± 0.1 15 0.3 12
Desloratadine 6.4 ± 0.1 13 0.02 15
Hydroxyzine 4.8 ± 0.1 11 0.14 12
Cetirizine No effect (at 100 µM) 13 0.12 14
Loratadine No effect (at 30 µM ) 31 28
Fexofenadine No effect (at 10 µM) 3 0.25 11
a- all estimates for Ki are statistically different (p < 0.001) except diphenhydramine and desloratadine (p = 0.135)
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A. The effects of diphenhydramine on the response of gland cell epithelium to histamine Figure 5
A. The effects of diphenhydramine on the response of gland cell epithelium to histamine. The responses to histamine, like 
those to ACh, are transient. However, the response to histamine decays more rapidly than that for ACh. Note that diphenhy-
dramine causes increasing inhibition with increasing concentration of inhibitor (A and inset A.1) without a decrease in maxi-
mum response of the histamine action. The range of concentrations at which inhibition occurs is similar to those that inhibited 
the ACh response (n = 9). Inset A.2 shows the Schild plot generated from diphenhydramine data. Note that when the slope 
of the line (red) shown in the inset was set to1, the calculated pA2 is 6.5 ± 0.2. However the least squares fit to these data had 
a slope of 1.6 (blue line) with estimated X intercept of -10.8 ± 2.4, suggesting that the underlying assumptions of the Schild 
analysis were not met. B. The effects of fexofenadine on gland cell responses to histamine. ∆ Isc in response to histamine are 
blocked by fexofenadine. Fexofenadine decreased the maximum ∆ Isc and caused a small shift to the right. Inset B shows the 
concentration response relationships derived from these data (n = 8).
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current is predominantly driven by M3 receptor activa-
tion, however these data do not rule out a role for the M1
subtype. These data do demonstrate the validity of this
preparation as a model system for determination of the
inhibition of muscarinic activity by drugs.
Fexofenadine, loratadine and cetirizine had no effect on
the concentration response relationships for ACh demon-
strating a lack of interaction with M3 receptors. Handley
et al., [15] also found that loratadine did not bind to mus-
carinic receptors. All other compounds tested in our
experiments competitively inhibited the increase in short-
circuit current caused by ACh. Our estimate of the Ki for
hydroxyzine is 15 µM. Kubo et al. [16] found that hydrox-
yzine had a Ki of 3.8 µM against muscarinic receptors in
the cerebral cortex using radioligand binding assays. The
estimated Ki  for desloratadine and diphenhydramine
inhibition of muscarinic receptors were not statistically
different (p=.135) with estimated Ki of in the range of 0.3
to 0.6 µM. Kubo et al. [16] measured a Ki for diphenhy-
dramine against QNB binding in the cerebral cortex,
indicative of all muscarinic receptor subtype binding, of
0.28 µM similar to our value of 0.6 µM for M3 muscarinic
receptor induced secretion from mucus gland cells. Carde-
lus et al. [17] estimated a similar potency for deslorata-
dine of approximately 0.2 µM (pA2= 6.7 ± 0.1) against
muscarinic-induced contraction of rabbit iris.
By contrast, estimates of affinity using the dose-ratio
method for the inhibition of the histamine receptor were
not done except for diphenhydramine. The underlying
assumptions of Schild analysis were clearly not met. Two
of these assumptions are: 1) the inhibition of a response
by the antagonist is competitive and 2) that during the
response, equilibrium of the antagonist and agonist with
the receptor is reached. These requirements are at least tac-
itly met for antihistamine binding to muscarinic receptors
and one or both are clearly not met in the case of hista-
mine receptors. The antagonists are known to bind com-
petitively with histamine receptors as shown in receptor
binding assays [16,18]. Therefore, it seems reasonable
that the second condition is not met. As shown for the ∆ Isc
response to histamine in Fig 5B, the responses decline rap-
idly after reaching a peak (within ~15 minutes at the high-
est concentration the response is near baseline). The
decline occurs even at low concentrations of histamine. At
least quasi-equilibrium conditions need to be established
within a very few minutes. Anthes et al. [18] demonstrated
that for desloratadine the off-rate for binding was quite
slow with only 37% of the desloratadine released from the
receptor in 6 hours. Christophe et al. [19] determined the
t1/2 for dissociation of cetirizine from the H1 receptor to
be 142 min. The slow rate of dissociation of the
antihistamine from the receptor resulted in a decreased
maximum response, with little apparent shift in the con-
centration response relationship. This is reminiscent of
non-competitive inhibition, since equilibrium cannot be
reached during the transient response. Thus, the calcula-
tion of pA2, using the method of Schild, is not valid for
antihistamine inhibition of histamine-induced increases
in short-circuit current. This conclusion was also drawn by
Miller et al. [20] for inhibition of the initiation of calcium
transients. However, qualitatively the potencies of the
antagonists can be estimated from the concentration
required to reduce the peak response by 50%, as shown in
Fig 5B. The rank order of potency using this method is:
desloratadine > cetirizine ≈  hydroxyzine > fexofenadine >
diphenhydramine > loratadine. This differs from the rank
order of affinities determined by Anthes et al. [18] using
radioligand binding assays: desloratadine > diphenhy-
dramine > hydroxyzine > cetirizine > loratadine (Kb
(nM):0.9, 2.5, 10, 47, 138, respectively). Our estimates of
potency are 10 to 100 times higher than the binding con-
stants reflecting the differences in methodology. The dif-
ference in the rank order of potency primarily is due to our
estimate of the potency of diphenhydramine using the
dose-ratio method. We estimated a pA2 for diphenhy-
dramine of 6.5 (300 nM) much higher than the Ki esti-
mates of 2.5–14 nM by others [16,18]. This suggests that
even in the case of diphenhydramine equilibrium
This figure shows the inhibition of histamine induced short  circuit current (∆ Isc) by different antihistamines at various  concentrations Figure 6
This figure shows the inhibition of histamine induced short 
circuit current (∆ Isc) by different antihistamines at various 
concentrations. These antihistamines concentration- depend-
ently inhibited maximum responses induced by histamine, the 
order of apparent efficiencies of histamine blockade were 
desloratadine > cetirizine ≈  hydroxyzine > fexofenadine > 
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conditions are not met. It should be noted that the esti-
mate of pA2 derived in this report assumed a slope of 1 for
the Schild plot. The slope by least square fit to the data
was 1.6 (p > 0.05 compared to unity) and curvilinear.
Therefore, diphenhydramine inhibition is also non-equi-
librium, and we expect that the actual pA2 for diphenhy-
dramine is in the range of 10.8 ± 2.4 (35 pM ~3.9 nM).
This conclusion was also drawn by Miller et al. [20]. They
found that diphenhydramine inhibited the histamine-
induced transient calcium response in an apparent non-
competitive manner.
Our findings suggest that of the antihistamines tested, the
rank order of selectivity for histamine over muscarinic
receptors is: cetirizine ≈  fexofenadine > loratadine >
desloratadine > hydroxyzine ≥  diphenhydramine. This
was derived from the ratio of the estimated potencies of
muscarinic inhibition and histaminergic inhibition. Since
fexofenadine, cetirizine and loratadine did not affect the
muscarinic response they were assumed to be the most
selective with cetirizine having the higher potency toward
histamine receptors.
Conclusion
It is likely that antihistamines with significant antimus-
carinic effects in this assay might show some antimus-
carinic actions in vivo. However, the antimuscarinic
actions probably will occur early after dosing and be short
lived, since as the plasma levels of the drugs decrease mus-
carinic inhibition would readily reverse, compared with
the comparatively slow release of antihistamines from the
histamine receptors. This would be true for most second
generation antihistamines and hydroxyzine, but would
not be true for diphenhydramine. This is born out by the
well known antimuscarinic action of diphenhydramine.
Thus, of the agents tested, those with the least antimus-
carinic action such as fexofenadine and cetirizine, may be
the most useful for treatment of allergic rhinitis and pos-
sibly as an adjunct drug in the treatment of asthma.
Methods
Isolation and culture of gland cells
Tracheal submucosal gland cells were isolated from the
tracheal epithelium of Yorkshire white male swine (30–40
kg) were. Animals were euthanized by exsanguination
after anesthesia with 5% isoflurane. The epithelium was
removed from the airway and gland cells were enzymati-
cally dissociated and isolated on discontinuous Percoll®
gradients by the methods of Yang et al. [13] and Chan and
Farley [21] with little modification. The cells were plated
on Millicell® inserts (0.04 µm pore size, 0.6 cm2 area)
coated with human placental collagen (20 µg/cm2) at a
density of ~106 cells per insert in PC-1 medium. After one
day in culture the medium from within the insert was
removed and the cells were grown at an air interface
[22,23]. As we have shown before after two days in culture
the epithelium had become confluent. Experiments were
performed after 3–5 days in culture.
Measurement of short-circuit current
Inserts were mounted in Ussing chambers (Costar) modi-
fied to accept the Millicell inserts. The chambers were
maintained at 37°C and continuously bubbled with 95%
O2/5% CO2. The bubbling also served to drive bubble-lift
circulation that quickly mixed drugs after addition to the
serosal or mucosal chambers, each having a volume of 8
ml. The transepithelial short circuit current was measured
using either VCC600 or VCC MC2 voltage clamp
amplifiers (Physiologic Instruments) connected to the
chambers via salt bridges and silver/silver chloride pellet
electrodes. 10 µM amiloride was added to the mucosal
solution in all experiments to inhibit sodium absorption.
All other compounds (ACh, histamine, antagonists) were
added to the serosal solution cumulatively from concen-
trated stock solutions (at least 1000× concentrated). The
increases in short circuit current in response to ACh or his-
tamine were measured as the peak currents obtained after
addition of agonist at each concentration, subtracted from
the baseline current measured prior to the addition of the
lowest concentration of agonist. The currents were nor-
malized to the area of the insert. Concentration response
curves were generated for each insert and an EC50 deter-
mined for each insert by fitting the data with a logistic
equation using Origin (Originlab). These data were then
used to calculate "dose ratio – 1" values for use in a Schild
plot [24] as discussed below.
Solutions and drugs
Hepes-buffered physiological saline was used for trans-
port, during dissection of trachea, and dissociation of
cells. It contained (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 10
Hepes; pH 7.4. A Krebs-Henseleit solution was used in all
experiments in the Ussing chamber having the following
composition (in mM): NaCl, 113; KCl, 4.8; CaCl2, 2.5;
NaHCO3, 18; KH2PO4, 1.2; MgSO4, 1.2; glucose, 5.5; and
mannitol, 30, pH adjusted to 7.4. This solution was bub-
bled with 95/5% O2/CO2 to give a pH of 7.4. Test com-
pounds and agonists were dissolved in Krebs-Henseleit
solution or DMSO. Equivalent volumes (never greater
than 0.1%) of DMSO added in control experiments were
without effect. All chemicals and drugs were obtained
from Sigma Chemical Corporation (St. Louis, MO) except
fexofenadine, desloratadine, loratadine and cetirizine, the
kind gift of Aventis Pharmaceutical Corporation.
Data analysis
Cumulative concentration-response relationships were
generated by measuring the peak to baseline increases in
short-circuit current induced after each concentration of
ACh or histamine was added cumulatively to the serosalBMC Pharmacology 2005, 5:8 http://www.biomedcentral.com/1471-2210/5/8
Page 10 of 10
(page number not for citation purposes)
bath. All data are expressed as mean ± SEM. Data were
normalized to the maximum peak current obtained for
each insert with the particular agonist being used. Only
one concentration-response relationship was generated
for each insert. EC50 values for each agonist were deter-
mined by fitting each individual data set with a logistic
function using the fitting functions in Origin™ (Origin-
Lab). These values were then used to estimate the shift of
the concentration-response relationships for ACh, by the
various antagonists used. The shifts in these relationships
were plotted as log (dose ratio-1) versus -log (inhibitor
concentration) according to the method of Arunlakshana
and Schild [24]. This should yield a plot with a slope of 1
and an X-intercept equal to pA2, an estimate of the antag-
onist affinity for the particular receptor being activated.
Slopes not significantly different from unity were found
for the inhibition of muscarinic receptors by all com-
pounds. This was not true for the inhibition of histamine
receptors. Quasi-equilibrium conditions must be met dur-
ing the response if the dose-ratio method is to be used.
These conditions are most likely never met for binding of
antihistamines with the histamine receptor due to the
transient nature of the response in comparison to the slow
off rate for unbinding of antihistamines such as deslorat-
adine [18]. An estimate of relative potency of the antihis-
tamines for the histamine receptor was determined from
the concentration of drug causing 50% reduction in the
maximum current compared with control inserts.
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